GlassScriptPhysician profile
Paula Barnes
NPI 1194068700
$182,113.27
in general payments reported to CMS, 2019-2025
15 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $1,419 · 2021: $757 · 2022: $803 · 2023: $832 · 2024: $100K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Travel and Lodging: $33K · Food and Beverage: $5,478 · Consulting Fee: $5,425.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $133,875.00 |
| Travel and Lodging | $33,326.12 |
| Food and Beverage | $5,478.28 |
| Consulting Fee | $5,425.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $178,142.98 | 2019-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $2,182.02 | 2020-2025 | Wegovy, Rybelsus, Ozempic |
| Currax Pharmaceuticals LLC | $680.83 | 2020-2025 | Contrave, Nexlizet, Nexletol |
| Boston Scientific Corporation | $186.90 | 2025 | Apollo Esg System |
| Endo Pharmaceuticals INC. | $183.23 | 2020-2022 | |
| Abbott Laboratories | $156.63 | 2023-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $140.80 | 2024 | Korlym |
| Aimmune Therapeutics, INC. | $133.83 | 2024 | |
| Vivus LLC | $118.45 | 2023-2025 | Qsymia |
| Kvk-Tech, INC. | $43.13 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $40.72 | 2023 | Imcivree |
| Abbvie INC. | $29.73 | 2021 | |
| Medicure Pharma INC. | $26.49 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $25.74 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.79 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.